Search clinical trials for: Formoterol MDI

Total 5864 results

Pearl Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD

Chronic Obstructive Pulmonary Disease

United States, Germany, United Kingdom, China, Taiwan, Korea, Republic of, Japan, Czechia, Hungary, Poland, Russian Federation
Sunovion

Completed

To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD

Chronic Obstructive Pulmonary Disease | Emphysema | Chronic Bronchitis

United States
Sunovion

Completed

Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease | Emphysema | Bronchitis

United States
Sunovion

Completed

A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States
Pearl Therapeutics, Inc.

Completed

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI

COPD
AstraZeneca

Recruiting

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS) (LOGOS)

Asthma

United States, China, Czechia, Germany, South Africa, United Kingdom, Mexico, Turkey, Colombia, Russian Federation, Brazil, Israel, Greece, Portugal, Austria, Costa Rica, Saudi Arabia, Slovakia, Sweden, Puerto Rico
Pearl Therapeutics, Inc.

Completed

Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

Chronic Obstructive Pulmonary Disease (COPD)

United States
Sunovion

Completed

Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD

Chronic Obstructive Pulmonary Disease | Emphysema | Chronic Bronchitis

United States
Organon and Co
Novartis

Completed

Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in Chronic Obstructive Pulmonary Disease (COPD) (Study P04230AM4)(COMPLETED)

Chronic Obstructive Pulmonary Disease (COPD)
Pearl Therapeutics, Inc.

Completed

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo

COPD
Organon and Co
Novartis

Completed

Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in COPD (Study P04229AM4)(COMPLETED)

Chronic Obstructive Pulmonary Disease (COPD)
Organon and Co

Completed

A Study of the Bronchodilator Effect of Formoterol Fumarate Used in Combination With Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P06476 AM2)

Asthma
Pearl Therapeutics, Inc.

Completed

Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD (telos)

Chronic Obstructive Pulmonary Disorder

United States, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Czechia
Pearl Therapeutics, Inc.

Completed

Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®

COPD

Japan
Organon and Co
Novartis

Completed

Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04073AM1)(COMPLETED)

Asthma
Pearl Therapeutics, Inc.

Completed

A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)

Chronic Obstructive Pulmonary Disorder

United States, Austria, Belgium, Canada, Denmark, Germany, Italy, Spain, Sweden, United Kingdom, Peru, Brazil, South Africa, Argentina, Russian Federation, Mexico, Puerto Rico, Chile, Norway
Organon and Co
Novartis

Completed

Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04334AM1)(COMPLETED)

Asthma
Pearl Therapeutics, Inc.

Completed

PT005 MDI Dose Ranging Versus Foradil Aerolizer Study

Chronic Obstructive Pulmonary Disease

United States
Sunovion

Completed

Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States
Pearl Therapeutics, Inc.

Completed

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Australia, United States, New Zealand
Pearl Therapeutics, Inc.

Completed

PT003 MDI Cardiovascular Safety Study

Chronic Obstructive Pulmonary Disease

United States, Australia, New Zealand
Organon and Co

Completed

A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241) (SPIRO)

Asthma
Organon and Co

Completed

Study of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI) in Adolescents & Adults With Persistent Asthma (P08212)

Asthma
AstraZeneca

Recruiting

A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS) (VATHOS)

Asthma

United States, Canada, Italy, Japan, Vietnam, Spain, Germany, Malaysia
AstraZeneca

Recruiting

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS) (KALOS)

Asthma

United States, Canada, Denmark, Hungary, New Zealand, Poland, Spain, Korea, Republic of, Philippines, Italy, Argentina, Bulgaria, India, Japan, Vietnam, Taiwan, Thailand, Peru, Chile, Puerto Rico, Belgium, Australia, Netherlands, Romania
Pearl Therapeutics, Inc.

Completed

A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos) (KRONOS)

COPD

United States, Canada, China, Japan
AstraZeneca
Parexel

Completed

A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFA

Chronic Obstructive Pulmonary Disease

United States
AstraZeneca

Completed

A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD

Chronic Obstructive Pulmonary Disease

United States, Peru, South Africa, Argentina, Mexico, Brazil, Chile, Colombia, Venezuela
AstraZeneca

Completed

An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma

Asthma

United States, Puerto Rico
AstraZeneca
Parexel

Completed

Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)

Chronic Obstructive Pulmonary Disease - COPD

United States
AstraZeneca
Parexel

Completed

A Study to Assess How Much Drug Reaches the Blood When Given From Symbicort pMDI With Spacer Compared to That of Symbicort pMDI Without Spacer in Healthy Volunteers

Study is Being Conducted in Healthy Volunteers

United Kingdom
Pearl Therapeutics, Inc.

Completed

Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects

Chronic Obstructive Pulmonary Disease

China
Brigham and Women's Hospital

Completed

Replication of the P04334 Asthma Trial in Healthcare Claims Data

Asthma

United States
Organon and Co
Novartis

Completed

Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04431AM2)(COMPLETED)

Asthma
AstraZeneca

Completed

Titratable Dosing in Moderate to Severe Asthmatics

Asthma
University of New Mexico

Withdrawn

Bronchoprotective Effect of Arformoterol in Children With Exercise-Induced Bronchospasm (EIB) (EIB)

Exercise-induced Bronchospasm

United States
Sunovion

Completed

A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States
AstraZeneca

Recruiting

A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a New Propellant (HFO) in Participants 40 to 80 Years of Age With COPD

COPD (Chronic Obstructive Pulmonary Disease)

United States, Turkey, Vietnam, Malaysia, Philippines, Thailand, Hungary, Mexico, Korea, Republic of, Argentina, Canada, India, Bulgaria, Poland
Henry Ford Health System
Sunovion

Terminated

A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients

Acute Asthma

United States
Mundipharma Research Limited

Completed

A Pharmacokinetic/Pharmacodynamic Inhaler Comparison Study in Healthy Volunteers

Asthma

United Kingdom
AstraZeneca

Terminated

Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD

Chronic Obstructive Pulmonary Disease

France
Allergy and Asthma Center of El Paso
GlaxoSmithKline

Unknown

Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)

Asthma

United States
Novartis
Schering-Plough

Completed

Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma

Asthma

United States, Colombia, Peru
AstraZeneca
Parexel

Completed

Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFA

Chronic Obstructive Pulmonary Disease

United States
AstraZeneca

Completed

A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate

Pulmonary Disease, Chronic Obstructive

United Kingdom
University of California, Los Angeles
Dey, L.P.

Withdrawn

Perforomist Versus Foradil Evaluated by Inspiratory Capacity and High Resolution Computed Tomography (HRCT)

Chronic Obstructive Pulmonary Disease | Emphysema | COPD | Chronic Bronchitis

United States
Organon and Co

Completed

Asthma Study Comparing Anti-Inflammatory Effects of 3 Doses of Mometasone Furoate/Formoterol Fumarate and Medium Dose Mometasone Furoate (Study P05122 AM1)(COMPLETED)

Asthma | Airway Inflammation
Chiesi Farmaceutici S.p.A.

Completed

A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) (FLASH)

Asthma

United States
University of Cambridge

Recruiting

Investigation of Differential Biology of Benign and Malignant Renal Masses Using Advanced Magnetic Resonance Imaging Techniques (IBM-Renal)

Kidney Cancer

United Kingdom

3

Subscribe